Business model

Strength in rare diseases

Paradigm shift to tackle rare diseases

Paradigm shift to tackle rare diseases

There have been ~10,000 human diseases reported to date, of which ~7,000 are rare disease defined by the number of patients in each country (e.g. US <200,000, Japan > 50,000). The patient number in each rare disease is small, but the entire number of the rare disease patients worldwide is estimated to be ~400 million. However,>95% of the rare disease has no effective treatment due to their small market sizes and burden to develop medicine against individual diseases.

Modalis Therapeutics develops therapeutics for the patients in this category. Our technology platform is easily applicable to different rare genetic disorders, enabling to develop medicines against the diseases quickly and effectively.

Business model

Expanding business opportunities in thee facets

Expanding business opportunities in thee facets

Our business takes two-way strategy; internal programs and external collaborations. The internal programs() originate in-house, and be licensed out to pharma partners at certain point. The collaboration programs()develop ground-up with partners, fusing expertise from the partner with our CRISPR-GNDM technology.